CD180 (RP105) Monoclonal Antibody (RP/14), PE, eBioscience™, Invitrogen™

Description

• Description: The RP/14 monoclonal antibody reacts with mouse CD180 (RP105)
• This 105 kDa type I transmembrane molecule is a member of the TLR family of proteins characterized by an extracellular domain with leucine-rich repeats and a cytoplasmic domain with homology to the type I IL-1 receptor
• RP105 physically associates with another molecule called MD-1 and is expressed on mature B cells, monocytes/macrophages and dendritic cells
• Ligation of RP105 with RP/14 protects B cells from irradiation- or dexamethasone-induced apoptosis, and drives them to proliferate
• B cells activated by RP105-ligation arrest their growth and undergo apoptosis when the antigen receptor is engaged
• The RP105/MD-1 complex in concert with TLR4 mediates B cell recognition and signaling of LPS
• Thus, RP105 is a signal transduction molecule and plays a role in regulation of B cell growth and death
• Applications Reported: The RP/14 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The RP/14 antibody has been tested by flow cytometric analysis of mouse splenocytes
• This can be used at less than or equal to 0.125 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family
• CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain
• CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells
• CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands
• Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size
• CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail
• The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1
• Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.